Related Experiment Videos
[Antimicrobial activities of cefozopran against Streptococcus pneumoniae from children]
Insights
Cefozopran (CZOP) demonstrates potent antimicrobial activity against penicillin-susceptible and resistant Streptococcus pneumoniae strains in children. This cephalosporin shows promise for treating pediatric infections caused by drug-resistant S. pneumoniae.
Area of Science:
- Microbiology
- Pharmacology
- Pediatrics
Context:
- Streptococcus pneumoniae is a leading cause of pediatric infections.
- Increasing antimicrobial resistance necessitates evaluating new therapeutic agents.
- Penicillin resistance in S. pneumoniae poses a significant clinical challenge.
Purpose:
- To evaluate the in vitro antimicrobial activity of cefozopran (CZOP) against clinical isolates of Streptococcus pneumoniae from children.
- To determine the minimum inhibitory concentrations (MICs) of CZOP and compare them to control drugs.
- To investigate the prevalence of penicillin-insensitive and macrolide-resistant S. pneumoniae strains.
Summary:
- Cefozopran exhibited potent activity against penicillin-susceptible S. pneumoniae (MIC90 < or = 0.025 µg/ml), outperforming ceftazidime, flomoxef, and erythromycin.
- Against penicillin-insensitive and resistant strains (MIC90 = 0.39 µg/ml), CZOP also showed superior activity compared to other tested agents.
- Macrolide resistance patterns varied by S. pneumoniae biovar, with higher frequencies in penicillin-resistant isolates.
Impact:
- Cefozopran demonstrates significant antimicrobial efficacy against multidrug-resistant Streptococcus pneumoniae, including penicillin-resistant strains.
- These findings suggest cefozopran's potential as an effective treatment option for pediatric infections caused by S. pneumoniae.
- The study highlights the importance of monitoring antimicrobial resistance patterns in pediatric pathogens.
Abstract:
In order to evaluate antimicrobial activity of cefozopran (CZOP), minimum inhibitory concentrations (MICs) of CZOP and control drugs were determined against Streptococcus pneumoniae from children that were isolated from October of 1995 to January of 1996. Determinations were made for the detection frequency of penicillin-insensitive or resistant strains in biovar utilizing hydrolysis products, and for the correlation of antibacterial susceptibility and macrolides (MLs)-resistant patterns. The results are summarized as follows; 1. MIC90 of CZOP was < or = 0.025 micrograms/ml against benzylpenicillin (PCG)-susceptible S. pneumoniae (PSSP, 50 strains). MIC distribution of CZOP against these strains was approximately equal to that of PCG, and showed stronger activities of CZOP than those of ceftazidime (CAZ), flomoxef (FMOX) and erythromycin (EM). 2. MIC90 of CZOP was 0.39 micrograms/ml against 50 strains of PCG-insensitive S. pneumoniae (PISP) and PCG-resistant S. pneumoniae (PRSP). Antimicrobial activities of CZOP against these strains were stronger than those of CAZ, FMOX, PCG and EM. 3. These isolated strains of PISP and PRSP did not show type III biovar, but showed types I and II. The detection frequency of MLs-constitutive resistant strains were high among type III PSSP and those of MLs-inductive resistant strains were high among types I and II PISP and PRSP. These data suggested that CZOP had strong antimicrobial activities against multiple drug resistant S. pneumoniae including penicillin-resistant strains. CZOP will be effective against S. pneumoniae which often are causative organisms in infections of children.